Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1995 May;4(3):191–195. doi: 10.1155/S0962935195000317

Platelet-activating factor: an inflammatory mediator in the acute phase of allergic conjunctivitis in a guinea-pig model

F Meijer 1,✉, J L van Delft 2, N J van Haeringen 1
PMCID: PMC2365638  PMID: 18475638

Abstract

The role of platelet-activating factor (PAF) as a mediator of increased conjunctival vascular permeability was investigated in a guinea-pig model of immediate hypersensitivity. Vascular permeability of the conjunctiva was determined by measuring the albumin content in lavage fluid (LF) after topical challenge with either PAF or ovalbumin. PAF produced a dose-dependent increase of the vascular permeability within minutes. Topical pretreatment with levocabastine, a potent histamine H1-antagonist demonstrated no effect towards the vascular permeability in response to PAF provocation. Pretreatment with eyedrops containing the specific PAF antagonist BN 52021 (1%) showed a significant inhibition of the vascular permeability (60.2%) and the clinical score (27.5%) after PAF challenge. In sensitized guinea-pigs, levocabastine showed a marked inhibition of both the vascular permeability (80.5%) and the clinical score (70%) after topical challenge with ovalbumin. BN 2021, although to a lesser extent, showed a similar effect towards the vascular permeability (26.8%) and the clinical score (28%) after antigen provocation. When BN 52021 and levocabastine were administered in combination, the vascular permeability was significantly decreased after antigen challenge in comparison with eyes pretreated with levocabastine alone. These results indicate that PAF plays a role in the acute phase of allergic conjunctivitis in the guinea-pig.

Full Text

The Full Text of this article is available as a PDF (598.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abelson M. B., George M. A., Schaefer K., Smith L. M. Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis. J Allergy Clin Immunol. 1994 Sep;94(3 Pt 1):458–464. doi: 10.1016/0091-6749(94)90201-1. [DOI] [PubMed] [Google Scholar]
  2. Abelson M. B., Schaefer K. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Surv Ophthalmol. 1993 Jul-Aug;38 (Suppl):115–132. doi: 10.1016/0039-6257(93)90036-7. [DOI] [PubMed] [Google Scholar]
  3. Braquet P., Touqui L., Shen T. Y., Vargaftig B. B. Perspectives in platelet-activating factor research. Pharmacol Rev. 1987 Jun;39(2):97–145. [PubMed] [Google Scholar]
  4. Gary R. K., Jr, Woodward D. F., Nieves A. L., Williams L. S., Gleason J. G., Wasserman M. A. Characterization of the conjunctival vasopermeability response to leukotrienes and their involvement in immediate hypersensitivity. Invest Ophthalmol Vis Sci. 1988 Jan;29(1):119–126. [PubMed] [Google Scholar]
  5. Hwang S. B., Li C. L., Lam M. H., Shen T. Y. Characterization of cutaneous vascular permeability induced by platelet-activating factor in guinea pigs and rats and its inhibition by a platelet-activating factor receptor antagonist. Lab Invest. 1985 Jun;52(6):617–630. [PubMed] [Google Scholar]
  6. Jager G. V., van Delft J. L., van Haeringen N. J., Verbeij N. L., Braquet P. Antagonist of platelet-activating factor prevents prostaglandin E2 induced ocular hypertension in rabbits. Prostaglandins. 1993 Jan;45(1):97–105. doi: 10.1016/0090-6980(93)90093-m. [DOI] [PubMed] [Google Scholar]
  7. Kroegel C., Yukawa T., Dent G., Chanez P., Chung K. F., Barnes P. J. Platelet-activating factor induces eosinophil peroxidase release from purified human eosinophils. Immunology. 1988 Jul;64(3):559–561. [PMC free article] [PubMed] [Google Scholar]
  8. Muller A., Meynier F., Bonne C. PAF-induced conjunctivitis in the rabbit is mediated by peptido-leukotrienes. J Ocul Pharmacol. 1990 Fall;6(3):227–232. doi: 10.1089/jop.1990.6.227. [DOI] [PubMed] [Google Scholar]
  9. Peplow P. V., Mikhailidis D. P. Platelet-activating factor (PAF) and its relation to prostaglandins, leukotrienes and other aspects of arachidonate metabolism. Prostaglandins Leukot Essent Fatty Acids. 1990 Oct;41(2):71–82. doi: 10.1016/0952-3278(90)90057-r. [DOI] [PubMed] [Google Scholar]
  10. Sheng Y., Birkle D. L. Intracamerally injected platelet activating factor (PAF) induces marked intraocular inflammatory reactions. Curr Eye Res. 1992 Nov;11(11):1067–1078. doi: 10.3109/02713689209015078. [DOI] [PubMed] [Google Scholar]
  11. Spencer D. A. An update on PAF. Clin Exp Allergy. 1992 May;22(5):521–524. doi: 10.1111/j.1365-2222.1992.tb00160.x. [DOI] [PubMed] [Google Scholar]
  12. Stock E. L., Roth S. I., Kim E. D., Walsh M. K., Thamman R. The effect of platelet-activating factor (PAF), histamine, and ethanol on vascular permeability of the guinea pig conjunctiva. Invest Ophthalmol Vis Sci. 1990 May;31(5):987–992. [PubMed] [Google Scholar]
  13. Thomas G., Church M. K. Platelet activating factor does not release histamine from human dispersed cutaneous mast cells. Clin Exp Allergy. 1990 Jul;20(4):377–382. doi: 10.1111/j.1365-2222.1990.tb02797.x. [DOI] [PubMed] [Google Scholar]
  14. Thörig L., van Agtmaal E. J., Glasius E., Tan K. L., van Haeringen N. J. Comparison of tears and lacrimal gland fluid in the rabbit and guinea pig. Curr Eye Res. 1985 Aug;4(8):913–920. doi: 10.3109/02713688509095259. [DOI] [PubMed] [Google Scholar]
  15. Woodward D. F., Ledgard S. E., Nieves A. L. Conjunctival immediate hypersensitivity: re-evaluation of histamine involvement in the vasopermeability response. Invest Ophthalmol Vis Sci. 1986 Jan;27(1):57–63. [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES